Cann Group Ltd
ASX:CAN

Watchlist Manager
Cann Group Ltd Logo
Cann Group Ltd
ASX:CAN
Watchlist
Price: 0.008 AUD -20% Market Closed
Market Cap: 12.2m AUD

Relative Value

The Relative Value of one CAN stock under the Base Case scenario is 0.027 AUD. Compared to the current market price of 0.008 AUD, Cann Group Ltd is Undervalued by 71%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CAN Relative Value
Base Case
0.027 AUD
Undervaluation 71%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
96
vs Industry
73
Median 3Y
3.1
Median 5Y
13.3
Industry
2.6
vs History
vs Industry
Median 3Y
-1.8
Median 5Y
-3.3
Industry
21.6
vs History
vs Industry
Median 3Y
-3
Median 5Y
-4.8
Industry
16.5
vs History
6
vs Industry
Median 3Y
-8.9
Median 5Y
-8.9
Industry
22.5
vs History
vs Industry
37
Median 3Y
1.8
Median 5Y
2.3
Industry
2.3
vs History
95
vs Industry
67
Median 3Y
3
Median 5Y
17.6
Industry
2.9
vs History
34
vs Industry
52
Median 3Y
2.1
Median 5Y
0
Industry
5.5
vs History
vs Industry
Median 3Y
-1.7
Median 5Y
-5
Industry
13
vs History
vs Industry
Median 3Y
-1.7
Median 5Y
-5
Industry
16.6
vs History
vs Industry
Median 3Y
-2.9
Median 5Y
-6.4
Industry
15.8
vs History
vs Industry
Median 3Y
-2.5
Median 5Y
-4
Industry
19.1
vs History
96
vs Industry
82
Median 3Y
0.4
Median 5Y
1.3
Industry
1.9

Multiples Across Competitors

CAN Competitors Multiples
Cann Group Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Cann Group Ltd
ASX:CAN
12.2m AUD 0.9 -0.5 -1.5 -1.5
US
Eli Lilly and Co
NYSE:LLY
999.6B USD 16.8 54.3 36.4 39.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
501.2B USD 5.4 20 16.3 21.2
CH
Roche Holding AG
SIX:ROG
254.4B CHF 4.1 27 11.5 13.5
UK
AstraZeneca PLC
LSE:AZN
210.1B GBP 4.8 29.9 108.3 158.5
CH
Novartis AG
SIX:NOVN
206.7B CHF 4.6 18.1 11.5 14.8
US
Merck & Co Inc
NYSE:MRK
250.5B USD 3.9 13.2 9.4 11.1
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.3 13 9.1 10.6
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
142.4B USD 2.3 14.5 7.4 10.1
P/E Multiple
Earnings Growth PEG
AU
Cann Group Ltd
ASX:CAN
Average P/E: 23.7
Negative Multiple: -0.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.3
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20
29%
0.7
CH
Roche Holding AG
SIX:ROG
27
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.9
38%
0.8
CH
Novartis AG
SIX:NOVN
18.1
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13.2
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13
4%
3.3
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.5
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Cann Group Ltd
ASX:CAN
Average EV/EBITDA: 438.7
Negative Multiple: -1.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.4
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.3
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.5
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.3
10%
10.8
CH
Novartis AG
SIX:NOVN
11.5
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.4
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.1
2%
4.6
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
1%
7.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Cann Group Ltd
ASX:CAN
Average EV/EBIT: 1 881.2
Negative Multiple: -1.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.1
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.2
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.5
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.5
23%
6.9
CH
Novartis AG
SIX:NOVN
14.8
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11.1
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
10.6
1%
10.6
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
8%
1.3